Table 4.

Analyses of clinical and pathological factors between ESRD (n = 19) vs. non-ESRD groups (n = 10)

Parameters	Non-ESRD (n = 10)	ESRD (n = 19)	P-value
Age	39.20±10.59	40.37±12.43	0.80
Past hypertension	6/10 (60.0%)	6/18 (33.3%)	0.243
Smoker	44.4%	53.3%	1.00
Serum creatinine at presentation	6.32±2.49	10.92±4.11	0.005
eGFR at presentation	13.31±9.89	6.45±4.62	0.07
Dialysis at onset	4/10 (40.0%)	17/18 (94.4%)	0.003
Severe retinopathy	22.2%	50.0% (8/16)	0.229
% sclerosed glomeruli	40.58±18.41	41.13±31.53	0.96
Crescents in biopsy	4/10	6/18	0.60
Ischaemic wrinkling	6/10 (60.0%)	9/18 (50.0%)	0.70
Periglomerular fibrosis	4/10 (40.0%)	6/18 (33.3%)	1.00
ATN	5/10 (50%)	4/18 (22.2%)	0.21
Interstitial fibrosis	4/10 (40%)	6/18 (33.3%)	0.59
Tubular atrophy	9/10 (90%)	17/18 (93.5%)	0.08
Thrombotic microangiopathy	6/10 (60%)	9/18 (50%)	0.70
C3 immune deposits	1/9 (11.1%)	5/16 (31.2%)	0.40
Vascular immune deposits	3/10 (42.9%)	4/18 (57.1%)	1.00
Final diagnosis*	Mal HTN 5, IgAN 3, DN 1, CKD 0	Mal HTN 4, IgAN 5, DN 2, CKD 4	0.42

*Mal HTN- more than 50% of the glomeruli were viable and had not shown any features of primary glomerular diseases (cellularity, thickening, expansion, and non-vascular immune deposits) hence considered as an accelerated phase of essential hypertension, IgAN- IgA Nephropathy, DN- Diabetic nephropathy, CKD- Histopathology specimens with significant glomerulosclerosis, interstitial fibrosis, tubular atrophy, non-contributory immunofluorescence and thence primary disease could not be determined labelled as chronic kidney disease